About: Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)
Creator	Joshi, Sunil Kumar Manikyam, Hemanth Kumar, Hemanth
Source	PMC
abstract	A novel coronavirus designated as SARS-CoV-2 in February 2020 by World Health organization (WHO) was identified as main cause of SARS like pneumonia cases in Wuhan city in Hubei Province of China at the end of 2019. This been recently declared as Global Pandemic by WHO. There is a global emergency to identify potential drugs to treat the SARS-CoV-2. Currently, there is no specific treatment against the new virus. There is a urgency to identifying potential antiviral agents to combat the disease is urgently needed. An effective and quick approach is to test existing antiviral drugs against. Whole genome analysis and alignment carried out using BLASTn, SMART BLAST and WebDSV 2.0 had shown more than 238 ORF’s coding for proteins mostly origin from Bat SARS coronavirus and root genomic origin from Archaea. Molecular docking results against protein targets Furin, papain like proteases, RdRp and Spike glycoprotein had shown paritaprevir, ritonavir, entecavir and chloroquine derivatives are the best drugs to inhibit multi targets of coronavirus infection including natural compounds corosolic acid, baicalin and glycyrrhizic acid with minimal inhibitory concentrations. Thus we propose use of paritaprevir, entecavir, ritonavir and chloroquine derivatives as best drug combination along with niacinamide, folic acid and zinc supplements to treat novel coronavirus infection. We also propose use of plant protease inhibitors (PI’s) and Anti-IL8, IL-6, IL-2 as future drug models against coronavirus.
has issue date	2020-03-30(xsd:dateTime)
has license	cc-by
sha1sum (hex)	06012e37c48504c6782326602f07954918d74f79
resource representing a document's title	Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)
has PubMed Central identifier	PMC7331973
schema:publication	J Pharm Drug Res
resource representing a document's body	covid:06012e37c48504c6782326602f07954918d74f79#body_text
is schema:about of	named entity 'plant' named entity 'infection' named entity 'ritonavir' named entity 'This' named entity 'antiviral drugs' named entity 'High' named entity 'ARCHAEA' named entity 'PROTEASES' named entity 'ENTECAVIR' named entity 'GLYCYRRHIZIC ACID' named entity 'GENOMIC' named entity 'China' named entity 'SARS-CoV-2' named entity 'drugs' named entity 'entecavir' named entity 'concentrations' named entity 'origin' named entity 'SARS-CoV-2' named entity 'Whole' named entity 'entecavir' named entity 'IL-2' named entity 'niacinamide' named entity 'SARS-CoV-2' named entity 'protein targets' named entity 'antiviral agents' named entity 'genome analysis' named entity 'Molecular docking' named entity 'protease inhibitors' named entity 'zinc supplements' named entity 'glycoprotein' named entity 'Bat' named entity 'coronavirus' named entity 'SARS' named entity 'glycyrrhizic acid' named entity 'antiviral drugs' named entity 'baicalin' named entity 'Genome Analysis' named entity 'lopinavir' named entity 'cell attachment' named entity 'PDB' named entity 'genetic algorithm' named entity 'influenza virus' named entity 'genome wide' named entity 'ritonavir' named entity 'SARS' named entity 'oseltamivir' named entity 'small molecules' named entity 'infection' named entity 'MERS' named entity 'nelfinavir' named entity 'entecavir' named entity 'serine protease' named entity 'papain' named entity 'NCBI' named entity 'Japan' named entity 'ORF' named entity 'receptor-mediated endocytosis' named entity 'Orf' named entity 'high throughput screening' named entity 'protein' named entity 'RdRp' named entity 'Lopinavir and Ritonavir' named entity 'papain' named entity 'swine' named entity 'difficulty in breathing' named entity 'World Health' named entity 'angiotensin converting enzyme 2' named entity 'hydroxychloroquine' named entity 'RNA' named entity 'respiratory failure' named entity 'furin' named entity 'anti-inflammatory drugs' named entity 'cytokines' named entity 'diarrhoea' named entity 'local search' named entity 'cell entry' named entity 'protein' named entity 'RdRp' named entity 'host cell' named entity 'Papain' named entity 'atom' named entity 'niacinamide' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software